SC
VERA icon

Stephens Consulting’s Vera Therapeutics VERA Stock Holding History

Stephens Consulting’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15
Closed -$361 – 1989
2025
Q1 		$361 Buy
+15
New +$482 ﹤0.01% 1267

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Stephens Consulting's VERA Position: Q2 2025 in Review

Stephens Consulting sold out of Vera Therapeutics (VERA) in Q2 2025, closing a stake of 15 shares — an estimated $361 sold.

Stephens Consulting first reported a position in VERA in Q1 2025 and held it in 1 quarter. The position peaked at $361 in Q1 2025. 172 funds tracked by Wall St. Rank hold VERA as of Q2 2025.

  • Stephens Consulting reported no remaining Vera Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 15 Vera Therapeutics shares in Q2 2025, an estimated $361.
  • Stephens Consulting first reported a position in Vera Therapeutics in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Vera Therapeutics position peaked at $361 in Q1 2025.
  • 172 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.